FDA-approved Sexual & reproductive

Nafarelin

Also written as Synarel

Nafarelin is a GnRH agonist. It is filed in this library under sexual & reproductive, a navigation topic rather than a statement of where it acts. As a regulatory matter it has at least one product approved by the FDA. It is also written as Synarel.

Regulatory status

Nafarelin has an FDA-approved product on the U.S. market, marketed as Synarel under application NDA019886.

The current label is held by Pfizer Laboratories Div Pfizer Inc.

From the FDA label

What Nafarelin is approved to treat

INDICATIONS AND USAGE FOR CENTRAL PRECOCIOUS PUBERTY (For Endometriosis, See Reverse Side ) SYNAREL is indicated for treatment of central precocious puberty (CPP) (gonadotropin-dependent precocious puberty) in children of both sexes. The diagnosis of central precocious puberty (CPP) is suspected when premature development of secondary sexual characteristics occurs at or before the age of 8 years in girls and 9 years in boys, and is accompanied by significant advancement of bone age and/or a poor adult height prediction. The diagnosis should be confirmed by pubertal gonadal sex steroid levels and a pubertal LH response to stimulation by native GnRH. Pelvic ultrasound assessment in girls usually reveals enlarged uterus and ovaries, the latter often with multiple cystic formations.Quoted from the FDA-approved prescribing information

The evidence

What has actually been published

One source on Nafarelin, resolved to its journal of record. The title is listed so you can judge the evidence rather than take a summary on trust.

Nearby

Other peptides acting on sexual & reproductive

Markers on this pathway

What is measured when the pituitary-gonadal axis is assessed

Nafarelin's FDA-approved label indicates it for a condition managed by suppressing or controlling gonadotropin release. These are the markers clinicians use when assessing the pituitary-gonadal axis. They are listed here so you can read about them, not as a statement that Nafarelin changes any of them.

Not sure what applies to you?

A 60-second questionnaire, reviewed by a U.S.-licensed physician.

Find my protocol

Educational reference only. This page explains what has been published about Nafarelin. It is not medical advice, it is not a diagnosis, and it carries no dosing information of any kind. OPTML does not offer or supply this compound unless a product page on this site says otherwise.

Treatment decisions are made by a licensed physician after an individual evaluation. Compounded preparations are not FDA-approved or evaluated by the FDA for safety, effectiveness, or quality. Individual results vary.

All 150 peptides